Presentation is loading. Please wait.

Presentation is loading. Please wait.

FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 1 OTC NSAIDs AND NEPHROTOXICITY Juan Carlos Pelayo, M.D. On Behalf Of The Division Of Cardio-Renal Drug Products.

Published byRuby Caren Pitts Modified over 9 years ago

Similar presentations

Presentation on theme: "FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 1 OTC NSAIDs AND NEPHROTOXICITY Juan Carlos Pelayo, M.D. On Behalf Of The Division Of Cardio-Renal Drug Products."— Presentation transcript:

1 FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 1 OTC NSAIDs AND NEPHROTOXICITY Juan Carlos Pelayo, M.D. On Behalf Of The Division Of Cardio-Renal Drug Products FDA OTC Advisory Committee - September 20, 2002

2 FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 2 QUESTIONS TO ADDRESS: ARE NON-PRESCRIPTION DOSES OF OTC NSAIDs NEPHROTOXIC? IF SO, WHAT IS THE OUTCOME OF A RISK- BENEFIT ANALYSIS?

3 FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 3 NSAID-INDUCED NEPHROTOXICITY (PRESCRIPTION DOSES) EDEMA HYPERKALEMIA  BLOOD PRESSURE  SERUM CREATININE / ARF PROTEINURIA / NS / INTERSTITIAL NEPHRITIS ACUTE PAPILLARY NECROSIS CRF

4 FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 4 AT RISK POPULATIONS VOLUME DEPLETION UNDERLYING KIDNEY DISEASE HEART FAILURE LIVER DYSFUNCTION WITH ASCITES ELDERLY PREGNANCY

5 FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 5 NSAID-INDUCED NEPHROTOXICITY (PRESCRIPTION DOSES) WHAT ARE THE RATES OF OCCURRENCE OF NSAID-RELATED KIDNEY ADVERSE EVENTS FOR PRESCRIPTION DOSES?

6 FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 6 NSAID-INDUCED NEPHROTOXICITY (PRESCRIPTION DOSES) STUDY DESIGN – PROSPECTIVE, RANDOMIZED, PLACEBO- CONTROLLED, PARALLEL GROUP DESIGN – TREATMENT DURATION 18 WEEKS – 361 HEALTHY SUBJECTS WITH OSTEOARTHRITIS WERE EVALUATED PER GROUP – RENAL ADVERSE EVENTS AS REPORTED BY THE INVESTIGATORS – IBUPROFEN 2400 mg/DAILY vs.. PLACEBO

7 FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 7 EDEMA 18 Weeks

8 FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 8 HYPERKALEMIA 18 Weeks

9 FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 9 HYPERTENSION 18 Weeks

10 FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 10  SERUM CREATININE 18 Weeks

11 FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 11 PROTEINURIA 18 Weeks

12 FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 12 NSAID-INDUCED NEPHROTOXICITY (PRESCRIPTION DOSES) ACUTE RENAL FAILURE 0% INTERSTITIAL NEPHRITIS 0% ACUTE PAPILLARY NECROSIS 0%

13 FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 13 OTC NSAIDs IBUPROFEN (1984) – Max. Dose 1200 mg/Daily (40% Prescription Dose) NAPROXEN (1994) – Max. Dose 600 mg/Daily (40% Prescription Dose) KETOPROFEN (1995) – Max. Dose 75 mg/Daily (25% Prescription Dose)

14 FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 14 NSAID-INDUCED NEPHROTOXICITY GRACIAS

Download ppt "FDA:ODE I:DCRDP:JCP:9/20/02:OTC NSAIDs: 1 OTC NSAIDs AND NEPHROTOXICITY Juan Carlos Pelayo, M.D. On Behalf Of The Division Of Cardio-Renal Drug Products."

Similar presentations

LECTURE FILES f:\callab\lectures\dhollo.. PHARMACOLOGY route of elimination –kidney –liver –both.

LECTURE FILES f:\callab\lectures\dhollo.. PHARMACOLOGY route of elimination –kidney –liver –both.
Edematous states & Diuretics. 2 basic steps in edema formation –Alteration in capillary haemodynamics that favors the movement of fluid from the vascular.

Edematous states & Diuretics. 2 basic steps in edema formation –Alteration in capillary haemodynamics that favors the movement of fluid from the vascular.
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):

Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
Chronic Renal Failure A. Definitions

Chronic Renal Failure A. Definitions
1 Acute Renal Failure At the end of this self study the participant will: Differentiate between pre, intra and post renal failure Describe dialysis modes:

1 Acute Renal Failure At the end of this self study the participant will: Differentiate between pre, intra and post renal failure Describe dialysis modes:
Overview of Aspirin and NSAID’s Label Warnings William E. Gilbertson, PharmD. Division OTC Drug Products 1.

Overview of Aspirin and NSAID’s Label Warnings William E. Gilbertson, PharmD. Division OTC Drug Products 1.
NSAIDs and GI and Renal Complications Lessons from Tennessee Medicaid population studies (and selected others)

NSAIDs and GI and Renal Complications Lessons from Tennessee Medicaid population studies (and selected others)
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 71 Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen.

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 71 Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen.
+ Case Study One Pediatric Patient’s Experience Shelley Chapman RN, BSN, CCTC Children’s Hospital of Wisconsin.

+ Case Study One Pediatric Patient’s Experience Shelley Chapman RN, BSN, CCTC Children’s Hospital of Wisconsin.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin 20-40 mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.

1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
The kidney maintains the vital functions of clearing excess body fluid and removing metabolic and exogenous toxins from the blood The kidney is particularly.

The kidney maintains the vital functions of clearing excess body fluid and removing metabolic and exogenous toxins from the blood The kidney is particularly.
Acute Tubular Necrosis (ATN) Dr. Belal Hijji, RN, PhD December 14 & 17, 2011.

Acute Tubular Necrosis (ATN) Dr. Belal Hijji, RN, PhD December 14 & 17, 2011.
This lecture was conducted during the Nephrology Unit Grand Ground by a Sub-intern under Nephrology Division, Department of Medicine in King Saud University.

This lecture was conducted during the Nephrology Unit Grand Ground by a Sub-intern under Nephrology Division, Department of Medicine in King Saud University.
An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,
HEPATO renal Syndrome Type I: Correct Diagnosis = Correct Management Stephen G. M. Wong BSc, BSc(Med), MD, MHSc, FRCPC Associate Professor of Medicine.

HEPATO renal Syndrome Type I: Correct Diagnosis = Correct Management Stephen G. M. Wong BSc, BSc(Med), MD, MHSc, FRCPC Associate Professor of Medicine.
Hepatorenal Syndrome Dr Allister J Grant Leicester Liver Unit

Hepatorenal Syndrome Dr Allister J Grant Leicester Liver Unit
DRAFT SLIDES FOR NDA 21-198 ADVISORY COMMITTEE PRESENATIONS.

DRAFT SLIDES FOR NDA ADVISORY COMMITTEE PRESENATIONS.

Similar presentations

Ads by Google